Physician profile
Thuc B Tu
NPI 1699979229
$4,427.14
in general payments reported to CMS, 2019-2025
31 companies · $776 in 2025
The $776 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $435 · 2020: $624 · 2021: $170 · 2022: $501 · 2023: $914 · 2024: $1,005 · 2025: $776.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,682 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,682.47 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $722.31 | 2020-2024 | Farxiga, Lokelma, Breztri |
| Amgen INC. | $705.30 | 2019-2025 | Krystexxa, Repatha, Repatha |
| Horizon Therapeutics Plc | $492.84 | 2019-2023 | Krystexxa |
| Ardelyx, INC. | $409.11 | 2023-2025 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $243.74 | 2022-2025 | |
| Aurinia Pharma U.S., INC. | $232.84 | 2021-2022 | |
| Novo Nordisk INC | $188.62 | 2024-2025 | Ozempic, Wegovy |
| Calliditas Therapeutics US INC. | $186.48 | 2022-2025 | Tarpeyo |
| Amarin Pharma, INC. | $165.38 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $136.70 | 2020-2022 | |
| Pfizer INC. | $111.66 | 2019-2025 | |
| Lilly USA, LLC | $94.65 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Eisai INC. | $90.14 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.37 | 2023-2025 | Jardiance, Tradjenta |
| Travere Therapeutics, INC. | $87.11 | 2023-2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $83.97 | 2023-2025 | Gvoke Hypopen |
| Inari Medical, INC. | $46.85 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Genentech USA, INC. | $45.73 | 2019-2021 | |
| Medtronic, INC. | $39.48 | 2023-2024 | Minimed 780g, Minimed 770g |
| Avion Pharmaceuticals | $38.01 | 2020 | |
| Paratek Pharmaceuticals, INC. | $25.71 | 2025 | Nuzyra |
| Phathom Pharmaceuticals, INC. | $24.00 | 2024 | Voquezna |
| Glaxosmithkline, LLC. | $23.12 | 2024 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $22.01 | 2024 | |
| Scpharmaceuticals INC. | $20.82 | 2025 | |
| Vifor Pharma, INC. | $19.03 | 2019 | |
| Fresenius USA Marketing, INC. | $17.67 | 2024 | Velphoro |
| Cequr Corporation | $17.25 | 2023 | Cequr Simplicity |
| Janssen Pharmaceuticals, INC | $16.83 | 2019 | |
| Akebia Therapeutics INC | $16.50 | 2020 | |
| Abbott Laboratories | $13.91 | 2025 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thuc Tu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.